Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells

European Journal of Pharmacology

Volumn 604, Issue 1-3, 2009, Pages 36-44

  Han, Young Su ^a   Lee, Chung Soo ^a  

^a Chung Ang University   (South Korea)

Author keywords

1 Methyl 4 phenylpyridinium; Antidepressant; Cell death; Different effect; Mitochondrial membrane permeability change

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CASPASE 3; CYTOCHROME C; FLUOXETINE; GLUTATHIONE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; TRANYLCYPROMINE;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL PROTECTION; CELL STRAIN; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NERVE CELL LESION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

1-METHYL-4-PHENYLPYRIDINIUM; AMITRIPTYLINE; ANIMALS; ANTIDEPRESSIVE AGENTS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL NUCLEUS; CELL SURVIVAL; DNA FRAGMENTATION; FLUOXETINE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIAL MEMBRANES; OXIDATIVE STRESS; PC12 CELLS; PERMEABILITY; RATS; TRANYLCYPROMINE;

EID: 59049103867     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.12.025     Document Type: Article

References (59)

1. Arimochi H., and Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur. J. Pharmacol. 541 (2006) 17-23
2. Bartholoma P., Erlandsson N., Kaufmann K., Rossler O.G., Baumann B., Wirth T., Giehl K.M., and Thiel G. Neuronal cell death induced by antidepressants: lack of correlation with Egr-1, NF-κB and extracellular signal-regulated protein kinase activation. Biochem. Pharmacol. 63 (2002) 1507-1516
3. Berthier A., Lemaire-Ewing S., Prunet C., Monier S., Athias A., Bessede G., Pais de Barros J.P., Laubriet A., Gambert P., Lizard G., and Neel D. Involvement of a calcium-dependent dephosphorylation of BAD associated with the localization of Trpc-1 within lipid rafts in 7-ketocholesterol-induced THP-1 cell apoptosis. Cell Death Differ. 11 (2004) 897-905
4. Birkmayer W., Knoll J., Riederer P., Youdim M.B., Hars V., and Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J. Neural Transm. 64 (1985) 113-127
5. Boggio P.S., Fregni F., Bermpohl F., Mansur C.G., Rosa M., Rumi D.O., Barbosa E.R., Odebrecht Rosa M., Pascual-Leone A., Rigonatti S.P., Marcolin M.A., and Araujo Silva M.T. Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression. Mov. Disord. 20 (2005) 1178-1184
6. Caley C.F. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann. Pharmacother. 31 (1997) 1481-1489
7. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta 1453 (1999) 49-62
8. Chiou S.H., Chen S.J., Peng C.H., Chang Y.L., Ku H.H., Hsu W.M., Ho L.L., and Lee C.H. Fluoxetine up-regulation expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived stem cell. Biochem. Biophys. Res. Commun. 343 (2006) 391-400
9. +. Brain Res. Mol. Brain Res. 119 (2003) 50-61
10. Constantini P.C., Chernyak B.C., Petronilli V., and Bernardi P. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J. Biol. Chem. 271 (1996) 6746-6751
11. Crow M.T., Mani K., Nam Y.J., and Kitsis R.N. The mitochondrial death pathway and cardiac myocyte apoptosis. Circ. Res. 95 (2004) 957-970
12. Das K.P., Freudenrich T.M., and Mundy W.R. Assessment of PC12 cell differentiation and neurite growth: a comparison of morphological and neurochemical measures. Neurotoxicol. Teratol. 26 (2004) 397-406
13. + actions. J. Neurosci. Res. 72 (2003) 89-97
14. Duman R.S., Heninger G.R., and Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54 (1997) 597-606
15. Fahn S., and Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1 (2004) 139-154
16. Fowler J.S., Volkow N.D., Logan J., Franceschi D., Wang G.J., MacGregor R., Shea C., Garza V., Pappas N., Carter P., Netusil N., Bridge P., Liederman D., Elkashef A., Rotrosen J., and Hitzemann R. Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci. 68 (2001) 2759-2768
17. Frazer A., and Benmansour S. Delayed pharmacological effects of antidepressants. Mol. Psychiatry Suppl. 1 (2002) S23-S28
18. Fu W., Luo H., Parthasarathy S., and Mattson M.P. Catecholamines potentiate amyloid β-peptide neurotoxicity: involvement of oxidative stress, mitochondrial dysfunction, and perturbed calcium homeostasis. Neurobiol. Dis. 5 (1998) 229-243
19. Gerber P.E., and Lynd L.D. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann. Pharmacother. 32 (1998) 692-698
20. Gibb W.R. Neuropathology of Parkinson's disease and related syndromes. Neurol. Clin. 10 (1992) 361-376
21. Greene L.A., and Tischler A.S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. U. S. A. 73 (1976) 2424-2428
22. Hall A.G. The role of glutathione in the regulation of apoptosis. Eur. J. Clin. Investig. 29 (1999) 238-245
23. Jacobsson S.O., and Fowler C.J. Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: effects of NMDA antagonists, antioxidants and MAO inhibitors. Neurochem. Int. 34 (1999) 49-62
24. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl 3 (2003) S26-S38
25. Kadota T., Yamaai T., Saito Y., Akita Y., Kawashima S., Moroi K., Inagaki N., and Kadota K. Expression of dopamine transporter at the tips of growing neurites of PC12 cells. J. Histochem. Cytochem. 44 (1996) 989-996
26. Kim R., Emi M., and Tanabe K. Role of mitochondria as the gardens of cell death. Cancer Chemother. Pharmacol. 57 (2006) 545-553
27. Kim Y.J., Ko H.H., Han E.S., and Lee C.S. Lamotrigine inhibition of rotenone- or 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death. Brain Res. Bull. 71 (2007) 633-640
28. Kolla N., Wei Z., Richardson J.S., and Li X.M. Amitriptyline and fluoxetine protects PC12 cells from cell death induced by hydrogen peroxide. J. Psychiatry Neurosci. 30 (2005) 196-201
29. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
30. + on mitochondrial permeability in brain mitochondria and cell viability in PC12 cells. Neurochem. Int. 40 (2002) 361-369
31. Levkovitz Y., Gil-Ad I., Zeldich E., Dayag M., and Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J. Mol. Neurosci. 27 (2005) 29-42
32. Lieberman A. Depression in Parkinson's disease - a review. Acta Neurol. Scand. 113 (2006) 1-8
33. Lindenboim L., Yuan J., and Stein R. Bcl-xS and Bax induce different apoptotic pathways in PC12 cells. Oncogene 19 (2000) 1783-1793
34. Lipman T., Tabakman R., and Lazarovici P. Neuroprotective effects of the stable nitroxide compound Tempol on 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in the nerve growth factor-differentiated model of pheochromocytoma PC12 cells. Eur. J. Pharmacol. 549 (2006) 50-57
35. Marcocci L., De Marchi U., Salvi M., Milella Z.G., Nocera S., Agostinelli E., Mondovi B., and Toninello A. Tyramine and monoamine oxidase inhibitors as modulators of the mitochondrial membrane permeability transition. J. Membr. Biol. 188 (2002) 23-31
36. Mignotte B., and Vayssière J.L. Mitochondria and apoptosis. Eur. J. Biochem. 252 (1998) 1-15
37. Mirza N.R., Nielsen E.Ø., and Troelsen K.B. Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog. Neuro-psychopharmacol. Biol. Psychiatry 31 (2007) 858-866
38. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
39. Murphy D.L., Mitchell P.B., and Potter W.Z. Novel pharmacological approaches to the treatment of depression. In: Bloom F.E., and Kupfer D.L. (Eds). Psychophamacology: The Fourth Generation of Progress (1995), Raven Press, New York, NY 1143-1153
40. Naoi M., Maruyama W., Akao Y., Yi H., and Yamaoka Y. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J. Neural Transm. Suppl. 71 (2006) 67-77
41. Oberhammer F.A., Pavelka M., Sharma S., Tiefenbacher R., Purchio A.F., Bursch W., and Schulte-Hermann R. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 5408-5412
42. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283 (1997) 1305-1322
43. Perona M.T., Waters S., Hall F.S., Sora I., Lesch K.P., Murphy D.L., Caron M., and Uhl G.R. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav. Pharmacol. 19 (2008) 566-574
44. Przedborski S., and Jackson-Lewis V. Mechanism of MPTP toxicity. Mov. Disord. 13 (1998) 35-38
45. Rong P., Bennie A.M., Epa W.R., and Barrett G.L. Nerve growth factor determines survival and death of PC12 cells by regulation of the bcl-x, bax, and caspase-3 genes. J. Neurochem. 72 (1999) 2294-2300
46. Sies H. Glutathione and its role in cellular functions. Free Radic. Biol. Med. 27 (1999) 916-921
47. Slattery D.A., Hudson A.L., and Nutt D.J. Invited review: the evolution of antidepressant mechanisms. Fundam. Clin. Pharmacol. 18 (2004) 1-21
48. Stefanova E., Potrebic A., Ziropadja L., Maric J., Ribaric I., and Kostic V.S. Depression predicts the pattern of cognitive impairment in early Parkinson's disease. J. Neurol. Sci. 248 (2006) 131-137
49. Storch A., Ludolph A.C., and Schwarz J. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J. Neural Transm. 111 (2004) 1267-1286
50. Tatsumi M., Groshan K., Blakely R.D., and Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340 (1997) 249-258
51. Tatton W.G., Chalmers-Redman R.M.E., Ju W.J.H., Mammen M., Carlile G.W., Pong A.W., and Tatton N.A. Propargylamines induce antiapoptotic new protein synthesis in serum-and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 301 (2002) 753-764
52. Tatton W.G., Chalmers-Redman R., and Tatton N.A. Neuroprotection by deprenyl and other propargylamines: glyceraldehydes-3-phosphate dehydrogenase rather than monoamine oxidase B. J. Neural Transm. 110 (2003) 509-515
53. Umeda M., Aoyama S., Kaiya T., Kohda K., Maruyama W., and Naoi M. Oxidation of 1-amino-4-phenyl-1,2,3,6-tetrahydropyridine, a 1-amino analog of MPTP, by type A and B monoamine oxidase. J. Neural Transm. 105 (1998) 1253-1264
54. Vaidya V.A., and Duman R.S. Depression-emerging insights from neurobiology. Br. Med. Bull. 57 (2001) 61-79
55. Vajda F.J., and Solinas C. Current approaches to management of depression in Parkinson's Disease. J. Clin. Neurosci. 12 (2005) 739-743
56. van Klaveren R.J., Hoet P.H.M., Pype J.L., Demedts M., and Nemery B. Increase in γ-glutamyltransferase by glutathione depletion in rat type II pneumocytes. Free Radic. Biol. Med. 22 (1997) 525-534
57. + toxicity in Vivo. Ann. N.Y. Acad. Sci. 899 (2000) 255-261
58. Wu Y., Shang Y., Sun S.G., Liu R.G., and Yang W.Q. Protective effect of erythropoietin against 1-methyl-4-phenylpyridinium-induced neurodegenaration in PC12 cells. Neurosci. Bull. 23 (2007) 156-164
59. Youdim M.B., and Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46 (2004) 1130-1140